Centro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (134)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  3. Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

    Microscopy and Microanalysis, Vol. 30, Núm. 1, pp. 151-159

  4. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

  5. Gastric metaplasia as a precursor of nonconventional dysplasia in inflammatory bowel disease

    Human Pathology, Vol. 143, pp. 50-61

  6. Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung Cancers

    Biomedicines, Vol. 12, Núm. 3

  7. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

  8. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441

  9. Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors

    Modern Pathology, Vol. 37, Núm. 5

  10. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

  11. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

  2. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA

    Genome Medicine, Vol. 15, Núm. 1

  3. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  4. Alterations in p53, Microsatellite Stability and Lack of MUC5AC Expression as Molecular Features of Colorectal Carcinoma Associated with Inflammatory Bowel Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  5. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 3, pp. 143-159

  6. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  7. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  8. Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  9. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86